Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Status:
RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Phase:
PHASE3
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Pakistan